🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thanks Nature Biotechnology for the great writeup! What an honor to be alongside stellar and dedicated founders, amazing investors and board, and the rigorous and relentless group of drug hunters that make up Nested Therapeutics!

A huge round of applause to our presenters for an exceptional job representing Nested Therapeutics at the AACR-NCI-EORTC Conference in Boston! The team’s passion, expertise and dedication shined through as they showcased our strides made with NST-628. #PrecisionMedicine

We are #hiring! This position will be responsible for developing and preparing global regulatory strategies for multiple programs. Reach out to learn more about us and our unique platform at [email protected]! #precisiononcology #clinicaldevelopment #biotech

Exciting news! The New England Venture Capital Association is set to host its 11th Annual NEVYs, and we've just received a nomination for the Emerging Life Science Company of the Year award! Curious to find out the results? Join us on December 7th at thenevys.com! 🏆 #NEVYs23 #LifeScienceAward

Happy #Thanksgiving from all of us at Nested Tx! As we head into the holiday season, let's take a moment to unwind and reflect on the impactful contributions we make every day. May this time be filled with relaxation, joy, and moments of #gratitude with loved ones!

We're excited to be featured in “Precision Oncology News” highlighting our co-founders, innovative platform and growing pipeline. Our lead compound NST-628, is anticipated to enter clinical trials in early 2024. Read more about us & the compelling science here!

Our list of the best R&D-intensive startups spun out of universities in 2022 includes companies correcting misfolded proteins, creating second-generation GPCR agonists and mining cancer genomes for novel targets #NBTAcademicStartups go.nature.com/3RyvVZA rdcu.be/ds1XJ

We are thrilled to share we’ve been recognized in BioSpace's prestigious NextGen Bio Class of 2024 of the hottest new life sciences companies. Cheers to an extraordinary journey ahead! #NextGen2024 #Innovation Learn more here: biospace.com/article/nextge…

Today, we announce the appointment of three members to our board of directors. “We look forward to partnering with them as we continue to build our pipeline and advance our first program into the clinic this year.” - Darrin Miles, CEO nestedtx.com/wp-content/upl…

We're proud to announce the FDA clearance of our IND Application for NST-628. Additionally, our CSO, will present pre-clinical data on NST-628 at the “New Drugs on the Horizon” Series at the 2024 AACR Annual Meeting. Stay tuned for more updates! nestedtx.com

FDA clears Nested Therapeutics Nested Therapeutics' IND application for NST-628, a promising treatment for solid tumors. #oncology #cancerresearch #FDA #FDANews #OncWeekly buff.ly/4cCnhBI

Just published with the #AACR24 New Drugs on the Horizon presentation— The pan-RAF-MEK Non-degrading #MolecularGlue NST-628 Is a Potent and Brain-penetrant Inhibitor of the RAS-MAPK Pathway with Activity Across Diverse RAS- and RAF-driven Cancers bit.ly/3Jbh9mh Nested Therapeutics

Congratulations to Klaus Hoeflich and co-authors at Nested Therapeutics on this simultaneous #AACR24 publication in Cancer Discovery!

Yesterday at AACR, we unveiled the preclinical data on our lead program, NST-628, during an oral presentation as part of the “New Drugs on the Horizon” series. For more insights, visit our website and stay tuned for more updates! nestedtx.com/wp-content/upl…

AACR24: Having entered the clinic last night, Nested Therapeutics's CEO discusses the preclinical profile of a brain-penetrant, pan-RAF/MEK molecular glue. #AACR24 Full video: biotechtv.com/post/nested-th…

Our CSO, @ Klaus Hoeflich, recently sat down with @ Sally Church on Nested’s progress. Check out the interview on Biotech Strategy Blog and discover our impressive journey from concept to clinic in just three years. #NST628 #NestedTherapeutics #biotech biotechstrategyblog.com/2024/04/transl…

Watch first author Meagan B. Ryan discuss her research article, NST-628 is a novel and potent pan-RAF-MEK inhibitor, published simultaneously at #AACR24: vimeo.com/932606757/4d0b… Nested Therapeutics